DCF 987

Drug Profile

DCF 987

Alternative Names: Dextran-1; Usherdex; Usherdex-4

Latest Information Update: 15 Dec 2009

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Polydex Pharmaceuticals
  • Developer BCY LifeSciences
  • Class Antibacterials; Expectorants; Glucans
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Bronchitis; Chronic obstructive pulmonary disease; Cystic fibrosis; Cystic fibrosis-associated respiratory tract infections

Most Recent Events

  • 09 Oct 2007 ALIGN Pharmaceuticals has been acquired by Cyclacel Pharmaceuticals
  • 18 May 2007 BCY LifeSciences terminates its licence for DCF 987
  • 25 Feb 2005 DCF 987 has been licensed to ALIGN Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top